• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 28-Nov-2022 11:25
SENSEX
62,504.30
210.66 (0.34%)
NIFTY
18,566.95
54.20 (0.29%)
    No Companies Visited

Back to news list
  • Biolexis (division of Stelis) partners with Akston for Covid-19 vaccine - AmbiVax-C&trade

    Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, and Biolexis, a division of Stelis Biopharma (Stelis), announced today that they have entered into a licensing, manufacturing and commercialization agreement for Akston's AKS-452, a protein subunit COVID-19 vaccine.

    Under the agreement, Biolexis gains the right to manufacture and commercialize AKS-452 (branded as AmbiVax-C™) in India and over 130 countries in Asia, Latin America, and Africa largely covering the low-and-middle income countries (LMICs). Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships.

    AKS-452 or AmbiVax-C™ is a first-of-its-kind thermostable COVID-19 vaccine developed for all parts of the world. AmbiVax-C™ is a SARS-CoV-2 protein subunit vaccine designed to induce a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein. As the primary locus for infection, the RBD is highly conserved among mutated forms of the virus. The studies on AmbiVax-C&trade have demonstrated robust antibody neutralization of variants, including Delta and Omicron, and the vaccine has been evaluated in multiple safety and efficacy studies in Netherlands and India across hundreds of subjects.



    Back to news list
Previous Stories :
More






Quick Links

Market Statistics

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
9769005430
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 28-Nov-2022
  •  ( 11:04) Hero MotoCorp hikes ex-showroom prices from Dec 1  
  •  ( 10:39) LIC pares stake in Siemens, DCM  
  •  ( 10:29) Oil & Gas stocks rise for 5th day  
  •  ( 10:29) Barometers trade with strong gains  
  •  ( 09:59) Lemon Tree Hotels signs new property in Jamshedpur  
  •  ( 09:32) Strong market breadth  
  •  ( 09:31) Indices trade sideways amid volatility  
  •  ( 08:34) Asian stocks trading lower  
  •  ( 08:11) Max Financial to acquire residual stake in Max Life  
Show News
28 November 2022 11:22
3145.00
(1.22 %)
892.50
(0.55 %)
6795.00
(0.72 %)
1652.35
(1.17 %)
842.45
(-0.51 %)
4407.40
(-0.24 %)
2642.30
(-1.47 %)
1127.55
(-0.03 %)
1596.05
(-1.31 %)
2527.10
(-0.37 %)
935.55
(0.62 %)
1185.35
(-0.23 %)
1648.15
(1.07 %)
340.75
(0.13 %)
1931.95
(0.18 %)
2057.40
(-0.24 %)
1258.10
(-0.20 %)
9090.90
(0.82 %)
19596.25
(0.35 %)
169.90
(0.06 %)
221.00
(0.20 %)
2690.10
(2.79 %)
603.55
(-0.64 %)
1033.75
(0.04 %)
105.10
(-1.04 %)
3403.60
(0.44 %)
1087.95
(0.75 %)
2601.95
(0.24 %)
6890.00
(0.24 %)
407.85
(1.29 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.